Exploring the Management of Statin Intolerant Patients: 2016 and Beyond

被引:8
|
作者
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Karagiannis, Asterios [1 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece
关键词
Statins; intolerance; muscle symptoms; transaminases; creatine kinase; new-onset diabetes; side effects; ezetimibe; proprotein convertase subtilisin kexin 9 inhibitors; non-statin lipid-lowering drugs; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; FATTY LIVER-DISEASE; BILE-ACID SEQUESTRANTS; CHRONIC KIDNEY-DISEASE; C-REACTIVE PROTEIN; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; VITAMIN-D LEVELS; CARDIOVASCULAR-DISEASE; DOUBLE-BLIND;
D O I
10.2174/1570161114666160226150028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Statins remain the cornerstone of lipid-lowering treatment. They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing every-other- day or once weekly may be another option. Several non-statin lipid-lowering drugs (ezetimibe, fibrates, colesevelam, niacin or proprotein convertase subtilisin kexin-9 inhibitors) are available as monotherapy or in combination with statins to achieve efficacy and tolerability.
引用
收藏
页码:523 / 533
页数:11
相关论文
共 50 条
  • [11] Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters
    Halcox, Julian P.
    CLINICAL LIPIDOLOGY, 2013, 8 (03) : 329 - 344
  • [12] Outcomes in Statin Intolerant Patients: The Cleveland Clinic Experience
    Mampuya, Warner
    Cho, Leslie
    Frid, David
    Huang, Julie
    Rocco, Michael
    Brennan, Danielle M.
    Hazen, Stanley L.
    CIRCULATION, 2011, 124 (21)
  • [13] Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia
    Florentin, Matilda
    Kostapanos, Michael S.
    Nakou, Eleni S.
    Elisaf, Moses
    Liberopoulos, Evangelos N.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2009, 14 (04) : 274 - 282
  • [14] Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias
    Wierzbicki, AS
    Doherty, E
    Lumb, PJ
    Chik, G
    Crook, MA
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (03) : 333 - 338
  • [15] Practical aspects in the management of statin-associated muscle symptoms (SAMS)
    Laufs, Ulrich
    Filipiak, Krysztof J.
    Gouni-Berthold, Ioanna
    Catapano, Alberico L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2017, 26 : 45 - 55
  • [16] Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD
    Markossian, Talar
    Burge, Nicholas
    Ling, Benjamin
    Schneider, Julia
    Pacold, Ivan
    Bansal, Vinod
    Leehey, David
    Stroupe, Kevin
    Chang, Alex
    Kramer, Holly
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (06) : 965 - 977
  • [17] NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient
    Cheeley, Mary Katherine
    Saseen, Joseph J.
    Agarwala, Anandita
    Ravilla, Sudha
    Ciffone, Nicole
    Jacobson, Terry A.
    Dixon, Dave L.
    Maki, Kevin C.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (04) : 361 - 375
  • [18] Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice
    Bosco, Giosiana
    Di Giacomo Barbagallo, Francesco
    Spampinato, Salvatore
    Lanzafame, Lorena
    Di Pino, Antonino
    Piro, Salvatore
    Purrello, Francesco
    Scicali, Roberto
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [19] PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients
    Gunta, Satya Preetham
    O'Keefe, James H.
    O'Keefe, Evan L.
    Lavie, Carl J.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2023, 79 : 12 - 18
  • [20] Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
    Ballantyne, Christie M.
    Banach, Maciej
    Mancini, G. B. John
    Lepor, Norman E.
    Hanselman, Jeffrey C.
    Zhao, Xin
    Leiter, Lawrence A.
    ATHEROSCLEROSIS, 2018, 277 : 195 - 203